Baidu
map

肝癌局部消融治疗规范专家共识

2011-07-29 MedSci原创 MedSci原创

 为了推动肝癌局部消融治疗的规范化,CSLC、CSCO和中华医学会肝病学分会肝癌学组共同发起,组织外科、肿瘤、超声、介入等多个学科的专家参与,起草制订了《肝癌局部消融治疗规范专家共识》,供参考、讨论。   局部消融治疗是借助影像技术的引导对肿瘤进行靶向定位,用物理或化学的方法杀死肿瘤组织的治疗。影像引导技术包括超声、CT和磁共振成像(MRI),而治疗途径包括经皮、经腹腔镜手术和经开腹手术三种。局

 为了推动肝癌局部消融治疗的规范化,CSLC、CSCO和中华医学会肝病学分会肝癌学组共同发起,组织外科、肿瘤、超声、介入等多个学科的专家参与,起草制订了《肝癌局部消融治疗规范专家共识》,供参考、讨论。   局部消融治疗是借助影像技术的引导对肿瘤进行靶向定位,用物理或化学的方法杀死肿瘤组织的治疗。影像引导技术包括超声、CT和磁共振成像(MRI),而治疗途径包括经皮、经腹腔镜手术和经开腹手术三种。局部消融治疗的特点包括:直接作用于肿瘤,具有高效快速的优势;治疗范围局限于肿瘤及其周围组织,对机体影响小,可以反复应用。局部消融治疗在过去的20年左右发展迅猛,已经成为继手术切除、介入治疗后的第3大肝癌治疗手段,而且由于其疗效确切,特别是在小肝癌的治疗方面,射频消融疗效与手术切除相近,因此被认为是小肝癌的根治性治疗手段之一。   治疗原理及分类   局部消融治疗按其原理可分为化学消融治疗和物理消融治疗。化学消融是指用化学的方法(即往病灶内注入化学物质如无水酒精、乙酸等),使局部组织细胞脱水、坏死、崩解,从而达到灭活肿瘤病灶的目的。目前应用于肝癌治疗的化学消融方法主要有瘤内无水酒精注射(Percut

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1844375, encodeId=385318443e5f1, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Thu Jul 05 00:07:00 CST 2012, time=2012-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405619, encodeId=bde514056199d, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Jul 31 07:07:00 CST 2011, time=2011-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421531, encodeId=60b71421531ab, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Sun Jul 31 07:07:00 CST 2011, time=2011-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597697, encodeId=5d89159e6974e, content=<a href='/topic/show?id=28986582e02' target=_blank style='color:#2F92EE;'>#消融治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65827, encryptionId=28986582e02, topicName=消融治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f07818523366, createdName=zhishijing, createdTime=Sun Jul 31 07:07:00 CST 2011, time=2011-07-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1844375, encodeId=385318443e5f1, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Thu Jul 05 00:07:00 CST 2012, time=2012-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405619, encodeId=bde514056199d, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Jul 31 07:07:00 CST 2011, time=2011-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421531, encodeId=60b71421531ab, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Sun Jul 31 07:07:00 CST 2011, time=2011-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597697, encodeId=5d89159e6974e, content=<a href='/topic/show?id=28986582e02' target=_blank style='color:#2F92EE;'>#消融治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65827, encryptionId=28986582e02, topicName=消融治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f07818523366, createdName=zhishijing, createdTime=Sun Jul 31 07:07:00 CST 2011, time=2011-07-31, status=1, ipAttribution=)]
    2011-07-31 docwu2019
  3. [GetPortalCommentsPageByObjectIdResponse(id=1844375, encodeId=385318443e5f1, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Thu Jul 05 00:07:00 CST 2012, time=2012-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405619, encodeId=bde514056199d, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Jul 31 07:07:00 CST 2011, time=2011-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421531, encodeId=60b71421531ab, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Sun Jul 31 07:07:00 CST 2011, time=2011-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597697, encodeId=5d89159e6974e, content=<a href='/topic/show?id=28986582e02' target=_blank style='color:#2F92EE;'>#消融治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65827, encryptionId=28986582e02, topicName=消融治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f07818523366, createdName=zhishijing, createdTime=Sun Jul 31 07:07:00 CST 2011, time=2011-07-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1844375, encodeId=385318443e5f1, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Thu Jul 05 00:07:00 CST 2012, time=2012-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405619, encodeId=bde514056199d, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Jul 31 07:07:00 CST 2011, time=2011-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421531, encodeId=60b71421531ab, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Sun Jul 31 07:07:00 CST 2011, time=2011-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597697, encodeId=5d89159e6974e, content=<a href='/topic/show?id=28986582e02' target=_blank style='color:#2F92EE;'>#消融治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65827, encryptionId=28986582e02, topicName=消融治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f07818523366, createdName=zhishijing, createdTime=Sun Jul 31 07:07:00 CST 2011, time=2011-07-31, status=1, ipAttribution=)]

相关资讯

叶胜龙:重视肝癌的个体化治疗

作者:复旦大学附属中山医院、复旦大学肝癌研究所叶胜龙 来源:中国医学论坛报      叶胜龙教授上海中山医院肝肿瘤内科主任、博士生导师,享受国务院政府特殊津贴。现任国际肝癌协会理事、中国抗癌协会常务理事、中国抗癌协会肝癌专业委员会名誉主任委员、SCO指导委员会委员等。   肝癌的治疗不仅要关注消除肿瘤本身,同时也须注重患者的肝功能保护,减少肝功能损害。肝癌的个体化治疗应依据循证医学证据,针

比较奥沙利铂联合5-氟尿嘧啶/亚叶酸钙(FOLFOX4方案)或阿霉素治疗国人晚期肝细胞癌的有效性和安全性的Ⅲ期临床研究

  报告者:南京八一医院全军肿瘤中心秦叔逵    时间:9 月17 日09:30~09:50    地点:16 区3 层1 号多功能厅   在乙型肝炎高发的中国,肝细胞癌(HCC)分别位列常见恶性肿瘤的第3位和主要癌症死亡的第2位。系统性化疗常常用于治疗晚期HCC,但迄今为止尚无标准的药物或方案被证实有生存获益。奥沙利铂(

肝细胞癌患者行放射性栓塞比化学栓塞病情进展减慢且能减轻毒性反应

背景与目的:化学栓塞是肝细胞癌(HCC)的标准治疗方案。(90)Y玻璃微球放射性栓塞是一种新的治疗方法,经动脉进行放射治疗。我们比较分析了这两种肝细胞癌治疗方法的疗效。 方法:收集463例经动脉行局部治疗(化学栓塞或放射性栓塞)9年以上的患者数据。排除了不适合进行比较和分析的245例患者(122例为接受化学治疗患者,123例为放射性治疗患者)的数据。随访患者的毒性症状,均进行基线图像分析并按时间

分子机制:肝癌为什么更偏爱男性?

文献标题:Cell cycle–related kinase is a direct androgen receptor–regulated gene that drives β-catenin/T cell factor–dependent hepatocarcinogenesis 文献出处:J Clin Invest. 2011 Jul 11. 期刊影响因子:2.643PMID:2

Baidu
map
Baidu
map
Baidu
map